|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 13, 2017 ) Hemophilia is a genetic disorder which impairs body`s ability to control blood clotting. Hemophilia usually occurs in males it is estimated that about 1 in 5000 males that are born each year contain hemophilia. Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild. About 80% of the hemophilia patients are considered to suffer from severe type.
Growing prevalence of the disease conditions and increasing usage of recombinant product is expected to drive the market growth. Advancements in the novel coagulating factors along with rising investments in Research and developments for hemophilia products are also driving the growth of the market. However lack of available medication, awareness of this disease and high cost of treatment are the key factors hindering the growth of the market. Advancements in gene therapy and approaching approval of drugs for treatment of hemophilia provide immense growth opportunities in the market.
View full report: http://www.marketdataforecast.com/market-reports/middle-east-and-africa-hemophilia-management-market-315/
Asia-Pacific hemophilia management market is analyzed on the basis of type of hemophilia and drug. By type of hemophilia it is further analyzed into Hemophilia A and Hemophilia B. On the basis of type of drug the market is segmented as Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A is the largest segment and projected to have the highest growth rate due to large number of patients suffering from it.
On the basis of geography Latin America hemophilia management market is analyzed under various regions namely Africa & Middle-East. Middle accounts for largest share within this region due to high disposable income and high awareness about the disease burden. Africa is estimated to be the fastest growing owing to increasing prevalence of the disease.
Free sample of the report is available at:http://www.marketdataforecast.com/market-reports/middle-east-and-africa-hemophilia-management-market-315/request-sample
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
Buy now: https://www.marketdataforecast.com/cart/buy-now/middle-east-and-africa-hemophilia-management-market-315
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
